Search Results

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced the publication, in the Journal of Clinical Chemistry, of the final results of the multicenter DETECT III clinical trial.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced its partnership with Alivio Health.

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the peer-reviewed journal Cancers, of the results of a clinical study on the utility of CTCs to detect disease relapse substantially earlier than what is currently possible with routine surveillance imaging, in patients with stage III melanoma.

Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, announced today the availability of its new CELLSEARCH CTC lab service to detect expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream.

Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR).

Menarini Silicon Biosystems Inc, a US company part of the Menarini Group and DIESSE Diagnostica Senese Società Benefit S.p.A. announced at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA has issued Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) codes for two of its CELLSEARCH advanced liquid biopsy tests which received preliminary pricing determination by the US Centers for Medicare and Medicaid Services (CMS). Issuing of these codes represents a decisive step towards gaining broad access to Medicare/Medicaid reimbursement.

Menarini Silicon Biosystems today announced that Dana-Farber Cancer Institute and the Multiple Myeloma Research Foundation presented data in an oral presentation at the 2021 ASH Annual Meeting.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstrating the clinical utility of CTC count as an independent prognostic factor in advanced breast cancer.